ESPR Esperion Therapeutics Inc.

-2.59  -6%
Previous Close 45.75
Open 45.28
Price To Book 6.58
Market Cap 1156846613
Shares 26,803,675
Volume 1,550,899
Short Ratio 9.91
Av. Daily Volume 544,962

SEC filingsSee all SEC filings

  1. 8-K - Current report 181038097
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988820
  3. 8-K - Current report 18986663
  4. 8-K - Current report 18864915
  5. 8-K - Current report 18864896

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 27, 2018. Primary endpoint met. LDL-C lowering 30%.
Bempedoic Acid - 1002-039
Phase 3 data released August 27, 2018.
Bempedoic Acid/ Ezetimibe (1002FDC-053)
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 data released May 23, 2018 - primary endpoint met. No fatal events. Discontinuation due to AE was greater than placebo.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability data released May 2, 2018. Primary endpoint met but high number of deaths vs placebo.
Bempedoic acid (ETC-1002-040) - Clear Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3 data released March 7, 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-048
Phase 3 data due October, 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-047

Latest News

  1. What Spark Therapeutics’ Valuation Trend Indicates
  2. Analyzing Axovant Sciences’ Valuation Metrics
  3. Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock?
  4. 3 Biotech Stocks That Could Soar in September
  5. Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol
  6. Esperion's combo therapy lowers cholesterol level by 35 pct, shares surge
  7. Esperion announces positive results for cholesterol-lowering therapy
  8. Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results
  10. Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
  11. Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications — Emerging Consolidated Expectations, Analyst Ratings
  12. The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings
  13. 3 Top Biotech Stocks to Buy Right Now
  14. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  15. Esperion Therapeutics: 2Q Earnings Snapshot
  16. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results
  17. Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors
  18. Options Traders Expect Huge Moves in Esperion Therapeutics (ESPR) Stock
  19. UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ESPR, ORA, MFGP, FLR, and REPH